Prevnar 13 Cuts Pneumococcal Rate in Kids

Source: MedPage Today

By: Petrochko, Cole


Use of the 13-valent pneumococcal conjugate vaccine (PCV13) is associated with reduced pneumococcal disease across all age groups, researchers reported at the IDWeek 2013 meeting. Within two years of being approved, the vaccine was associated with a 59 percent reduction in invasive pneumococcal disease-related hospitalizations in children under age five and a 25 percent reduction in related hospitalizations in adults. In addition, vaccination was associated with a 19 percent reduction in hospitalization related to all-cause pneumonia in children five and under. The study authors looked at the effects of vaccination on pneumococcal-related diseases and disease outcomes, including invasive pneumococcal disease, noninvasive lobar pneumonia, empyema, and all-cause pneumonia. The researchers reported that “substantial herd immunity was achieved,” as in “90 percent of total invasive pneumococcal disease reduction which occurred in older children and adults who were not immunized.”

Copyright © 2014 Information, Inc.